Latest Doxorubicin Stories
The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients.
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease.
A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.
Breast cancer cells that mutate to resist drug treatment survive by establishing tiny pumps on their surface that reject the drugs as they penetrate the cell membrane – making the cancer insensitive to chemotherapy drugs even after repeated use.
Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals Cambridge, MA (PRWEB) August 08, 2011 Merrimack Pharmaceuticals, Inc.
- The governor of a province or people.